Qualigen Therapeutics (Ritter Pharmaceuticals) ^{Priced, Nasdaq: QLGN}

Developing an oral therapy that reduces the symptoms of lactose intolerance.

Industry: Health Care

First Day Return: -0.8%

QLGN

Developing an oral therapy that reduces the symptoms of lactose intolerance.

IPO News for Qualigen Therapeutics (Ritter Pharmaceuticals)

Ritter Pharmaceuticals prices IPO at downwardly revised price of $5; now has $39 million market cap 06/24/15
Week ahead: As many as 17 IPOs could price during the week of June 22 06/22/15
Ritter Pharmaceuticals drops proposed IPO price; market cap down 45% to $39 million 06/19/15

IPO Data
IPO Date	06/23/2015
Offer Price	IPO Intelligence Only
Price Range	IPO Intelligence Only
Offer Shares (mm)	IPO Intelligence Only
Deal Size ($mm)	$20
Lock-Up Date	IPO Intelligence Only
Street Research	IPO Intelligence Only

Underwriters
IPO Intelligence Only

Company Data
Headquarters	Los Angeles, CA, United States
Founded	2004
Employees at IPO	5
Website www.ritterpharmaceuticals.com

IPO News for Qualigen Therapeutics (Ritter Pharmaceuticals)

Qualigen Therapeutics (Ritter Pharmaceuticals) (QLGN) Performance